Interview, Other
Bullish Options Trades Slow amid AI Uncertainty
- Implied volatility heading into earnings is estimated to be fair and aligned with recent quarterly averages.
- AI demand is projected to remain robust while intensifying competition, leading to increased dispersion in market reactions.
- Investor focus is expected to shift toward financing structures of AI expansion to identify long-term winners and losers.
- Credit market supply is anticipated to significantly exceed demand, resulting in wider credit spreads.
- Post-pandemic echo boom demand may fail to keep pace with supply, creating uncertainty regarding future outcomes.
- Retail community volumes are forecast to remain approximately 20% below late June levels, signaling a decline in sponsorship for the AI trade.
- Retail and institutional call buying activity are both expected to decline, though leveraged ETF volumes are projected to remain strong.
- The primary market narrative has been driven by call buying for right-tail opportunities, with the recent pullback in implied volatility attributed to risk reduction on the call side rather than put buying.
- Increased put buying in recent weeks indicates rising nervousness regarding market conditions through year-end.
- Current absolute volatility levels are low with fair market distributions, creating an opportunity to deploy capital via options for views spanning from the present through year-end.
- A risk exists that a flat or declining market could trigger a self-fulfilling cycle of put buying that negates the value of prior call purchases.
- The momentum factor is expected to see greater dispersion requiring more precise, surgical exposure strategies via options compared to the sharp moves in Q1 and Q2.
- Biotech is identified as a sector outside AI offering secular opportunities similar to previous AI trades.
- The biotech sector may benefit from lower interest rates and increased M&A activity in the near future.
- AI-driven advancements in drug discovery are expected to attract additional capital to the biotechnology area.
- Institutional opinions may change without notice and past performance does not guarantee future results.